IL6 and dermatitis: Even though psoriasis-like eruptions have been reported as a paradoxical phenomenon after use of tocilizumab44, our experiments and the previous clinical case report42 demonstrate that IL-6 blockade therapy during the initial phase of PD-1 signal blockade-induced psoriasis-like dermatitis may rapidly reduce the severity of irAE and therefore, result in shorter interruptions of cancer treatments.